We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Spark Therapeutics Gets $15M Milestone Payment from Pfizer
Read MoreHide Full Article
Spark Therapeutics received a $15 million milestone payment from partner Pfizer Inc. (PFE - Free Report) for achieving a pre-specified safety and efficacy profile in the phase I/II study on SPK-9001, which is being evaluated for the treatment of hemophilia B.
Spark Therapeutics’ share price has gained 60% in the past one year compared with Zacks classified Medical-Biomedical and Genetics industry’s fall of 22.1%.
We note that Pfizer and Spark Therapeutics entered into a collaboration in 2014 under which Spark Therapeutics will be responsible for conducting all phase I/II studies for any candidate that may be developed under its SPK-FIX program. On the other hand, Pfizer will be accountable for pivotal studies, any regulatory activity and global commercialization of any product that may result from the collaboration.
As per the license agreement, Spark Therapeutics is entitled to receive up to $230 million for development and commercial milestones related payments, as well as royalties calculated as a percentage of net sales on any potential SPK-FIX products.
SPK-9001 is a novel bio-engineered adeno-associated virus (AAV) that has received breakthrough therapy and orphan product designations from the FDA.
Zacks Rank & Key Picks
Spark Therapeutics currently carries a Zacks Rank #2 (Buy). Other favorably-ranked stocks in the health care sector include Cambrex Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex sports a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price was up 26.7% in the past one year.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5% respectively over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 35.8% in the past one year.
Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Spark Therapeutics Gets $15M Milestone Payment from Pfizer
Spark Therapeutics received a $15 million milestone payment from partner Pfizer Inc. (PFE - Free Report) for achieving a pre-specified safety and efficacy profile in the phase I/II study on SPK-9001, which is being evaluated for the treatment of hemophilia B.
Spark Therapeutics’ share price has gained 60% in the past one year compared with Zacks classified Medical-Biomedical and Genetics industry’s fall of 22.1%.
We note that Pfizer and Spark Therapeutics entered into a collaboration in 2014 under which Spark Therapeutics will be responsible for conducting all phase I/II studies for any candidate that may be developed under its SPK-FIX program. On the other hand, Pfizer will be accountable for pivotal studies, any regulatory activity and global commercialization of any product that may result from the collaboration.
As per the license agreement, Spark Therapeutics is entitled to receive up to $230 million for development and commercial milestones related payments, as well as royalties calculated as a percentage of net sales on any potential SPK-FIX products.
SPK-9001 is a novel bio-engineered adeno-associated virus (AAV) that has received breakthrough therapy and orphan product designations from the FDA.
Zacks Rank & Key Picks
Spark Therapeutics currently carries a Zacks Rank #2 (Buy). Other favorably-ranked stocks in the health care sector include Cambrex Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex sports a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price was up 26.7% in the past one year.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5% respectively over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 35.8% in the past one year.
SPARK THERAPEUT Price
SPARK THERAPEUT Price | SPARK THERAPEUT Quote
Zacks' Best Investment Ideas for Long-Term Profit
Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>